Does oral lansoprazole really reduce gastric acidity in VLBW premature neonates?
Premature neonates of very low birth weight (VLBW) whose treatment required the use of naso-gastric tube feeding were investigated. 10 infants suspected of having GERD (gastroesophageal reflux) received oral lansoprazole therapy by tube administration. 9 other infants formed a control group. In the treated group a fasting pH was determined before treatment and again after 7 days treatment. The control group was similarly assessed at an interval of 7 days. Despite acid reduction, the post-treatment pH mean of 1.31 would continue to pose a threat to the esophageal mucosa. The physiology of neonatal acid secretion is discussed to explain these findings.
Faculty of Medicine, AIMST University, Batu 3 Vz, Bukit Air Nasi, Jalan Bedong Semeling, 08100 Bedong, Kedah Darul Aman, Malaysia.
Sock Ying
SY
Tham
Ian M
IM
Rogers
K F
KF
Samuel
A
A
Singh
King Kok
KK
Ong
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D005744:Gastric Acid / Q000737:chemistry / Q000378:metabolism*; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D006863:Hydrogen-Ion Concentration / Q000187:drug effects; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000188:drug therapy* / Q000503:physiopathology; D019102:Infant, Very Low Birth Weight; D064747:Lansoprazole; D008297:Male
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D064747:Lansoprazole